Through the 90-day period concluding February 07, 2026, Pacira BioSciences's top three insider stakeholders include Chief Executive Officer Frank D. Lee (399.01K shares), Ceo And Chairman David M Stack (186.48K shares), Chief Medical Officer Jonathan Slonin (172.36K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Frank D. Lee | Chief Executive Officer | 399,013 | 03 Feb, 2026 |
| David M Stack | Ceo And Chairman | 186,481 | 16 Jun, 2023 |
| Jonathan Slonin | Chief Medical Officer | 172,355 | 03 Feb, 2026 |
| Kristen Williams | Chief Administrative Officer | 131,303 | 03 Feb, 2026 |
| Daryl Gaugler | Chief Operating Officer | 115,443 | 06 Jan, 2025 |
| Shawn Cross | Chief Financial Officer | 56,250 | 11 Dec, 2025 |
| Roy Winston | Chief Medical Officer | 52,440 | 04 Aug, 2023 |
| Lauren Riker | Senior Vice President And Finance | 52,313 | 03 Feb, 2026 |
| Charles A. Iii Reinhart | Chief Financial Officer | 51,867 | 13 Jun, 2024 |
| Brendan Teehan | Chief Commercial Officer | 49,220 | 03 Feb, 2026 |
| Charles Anthony Laranjeira | Chief Technical Officer | 41,752 | 16 Jun, 2022 |
| Dennis Mcloughlin | Chief Customer Officer | 38,115 | 07 Jun, 2023 |
| Mark A. Kronenfeld | 34,901 | 13 Jun, 2025 | |
| Ronald J. Jr. Ellis | Chief Strategy Officer | 30,909 | 07 Jun, 2023 |
| Donald C. Manning | Chief Medical Officer | 29,520 | 11 Jun, 2021 |
| Max Reinhardt | President And Rest Of World | 29,225 | 07 Jun, 2023 |
| Laura Brege | 23,715 | 13 Jun, 2025 | |
| Gary W Pace | 22,127 | 08 Mar, 2024 | |
| Mark Froimson | 20,636 | 13 Jun, 2025 | |
| John P Phd Longenecker | 18,823 | 07 Mar, 2022 | |
| Christopher Christie | 16,654 | 13 Jun, 2025 | |
| Michael J. Yang | 13,393 | 13 Jun, 2025 | |
| Yvonne Greenstreet | 13,247 | 08 Jun, 2022 | |
| Anthony Molloy | Chief Lgl & Compliance Officer | 12,877 | 07 Jun, 2023 |
| Paul J Hastings | 12,724 | 13 Jun, 2024 | |
| Marcelo Bigal | 11,393 | 11 Aug, 2025 | |
| Alethia Young | 11,393 | 13 Jun, 2025 | |
| Abraham Ceesay | 9,039 | 08 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Feb, 2026 | Kristen Williams | Common Stock | D | 13,137 | $20.53 | 131,303 | D | S |
| 02 Feb, 2026 | Lauren Riker | Common Stock | D | 4,000 | $20.81 | 52,313 | D | S |
| 30 Jan, 2026 | Kristen Williams | Common Stock | D | 17,134 | $20.54 | 144,440 | D | F |
| 30 Jan, 2026 | Lauren Riker | Common Stock | D | 2,751 | $20.54 | 56,313 | D | F |
| 30 Jan, 2026 | Frank D. Lee | Common Stock | D | 41,488 | $20.54 | 399,013 | D | F |
| 30 Jan, 2026 | Jonathan Slonin | Common Stock | D | 6,168 | $20.54 | 172,355 | D | F |
| 30 Jan, 2026 | Brendan Teehan | Common Stock | D | 5,182 | $20.54 | 49,220 | D | F |
| 05 Jan, 2026 | Lauren Riker | Common Stock | D | 1,416 | $24.24 | 59,064 | D | S |
| 02 Jan, 2026 | Lauren Riker | Common Stock | D | 159 | $24.46 | 60,480 | D | F |
| 02 Jan, 2026 | Frank D. Lee | Common Stock | D | 9,272 | $24.46 | 440,501 | D | F |
| 02 Jan, 2026 | Jonathan Slonin | Common Stock | D | 381 | $24.46 | 178,523 | D | F |
| 31 Dec, 2025 | Brendan Teehan | Common Stock | A | 402 | $10.76 | 54,402 | D | A |
| 10 Dec, 2025 | Shawn Cross | - | - | 65,354 | D | |||
| 10 Dec, 2025 | Shawn Cross | - | - | 56,250 | D | |||
| 10 Dec, 2025 | Shawn Cross | Common Stock | A | 9,104 | $16.45 | 65,354 | D | M |
| 10 Dec, 2025 | Shawn Cross | Common Stock | D | 9,104 | $25.14 | 56,250 | D | S |
| 09 Dec, 2025 | Shawn Cross | - | - | 56,250 | D | |||
| 09 Dec, 2025 | Shawn Cross | Common Stock | D | 15,896 | $25.03 | 56,250 | D | S |
| 09 Dec, 2025 | Shawn Cross | Common Stock | A | 15,896 | $16.45 | 72,146 | D | M |
| 17 Nov, 2025 | Jonathan Slonin | Common Stock | D | 3,960 | $24.09 | 178,367 | D | S |